Real-world efgartigimod use in adults with CIDP

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, noninterventional study that will follow adults with CIDP who are starting efgartigimod in routine practice for up to two years. Treatment choices and timing are left to participants and their physicians according to local standard of care. The study will document each participant's treatment journey, clinical outcomes, and healthcare service use after initiating efgartigimod. Enrollment is open at selected sites including a U.S. virtual site and German hospital centers, and participants must be efgartigimod‑naïve at baseline.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥18 years at time of providing informed consent
* Diagnosed with CIDP
* Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country
* Efgartigimod treatment-naïve at time of screening

Exclusion Criteria:

* Polyradiculoneuropathy due to any other cause(s)
* Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod

Where it's running

• PPD Virtual
  Wilmington, North Carolina, United States Recruiting
• Jüdisches Krankenhaus Berlin
  Berlin, Germany Recruiting
• Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH
  Bochum, Germany Recruiting
• UK-RUB - Katholisches Klinikum Bochum - St. Josef Hospital
  Bochum, Germany Recruiting
• Universitätsklinikum Köln
  Cologne, Germany Recruiting
• Universitätsklinikum Düsseldorf
  Düsseldorf, Germany Recruiting

Study contacts

• Study coordinator: Sabine Coppieters, MD
• Email: clinicaltrials@argenx.com
• Phone: 857-350-4834

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Empasiprubart for adults with CIDP

  This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.

  Recruiting at 94 sites Phase 3 argenx · Birmingham, Alabama and 93 other locations · NCT07091630

• Weekly subcutaneous XEMBIFY versus every-3-week intravenous Gamunex-C for CIDP

  This will test whether weekly under-the-skin XEMBIFY gives similar blood IgG levels as Gamunex-C given into a vein every three weeks in people with CIDP.

  Recruiting at 15 sites Phase 3 Grifols Therapeutics LLC · Rancho Mirage, California and 15 other locations · NCT07540221

• BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

  This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT07022197

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Empasiprubart versus IVIg for treating CIDP in adults

  This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.

  Recruiting at 107 sites Phase 3 argenx · Birmingham, Alabama and 106 other locations · NCT06920004

• Using rituximab to achieve remission in patients with chronic inflammatory demyelinating polyneuropathy

  This study is testing if rituximab can help people with chronic inflammatory demyelinating polyneuropathy feel better and reduce their need for other treatments.

  Recruiting Phase 3 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT06714838

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.